JP2014518630A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518630A5
JP2014518630A5 JP2014513202A JP2014513202A JP2014518630A5 JP 2014518630 A5 JP2014518630 A5 JP 2014518630A5 JP 2014513202 A JP2014513202 A JP 2014513202A JP 2014513202 A JP2014513202 A JP 2014513202A JP 2014518630 A5 JP2014518630 A5 JP 2014518630A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014513202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518630A (ja
JP6254522B2 (ja
Filing date
Publication date
Priority claimed from GBGB1109238.4A external-priority patent/GB201109238D0/en
Application filed filed Critical
Publication of JP2014518630A publication Critical patent/JP2014518630A/ja
Publication of JP2014518630A5 publication Critical patent/JP2014518630A5/ja
Application granted granted Critical
Publication of JP6254522B2 publication Critical patent/JP6254522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014513202A 2011-06-01 2012-06-01 ヒト化抗cd52抗体 Active JP6254522B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161492005P 2011-06-01 2011-06-01
GB1109238.4 2011-06-01
GBGB1109238.4A GB201109238D0 (en) 2011-06-01 2011-06-01 Antibodies
US61/492,005 2011-06-01
PCT/EP2012/060345 WO2012164063A1 (en) 2011-06-01 2012-06-01 Humanised anti-cd52 antibodies

Publications (3)

Publication Number Publication Date
JP2014518630A JP2014518630A (ja) 2014-08-07
JP2014518630A5 true JP2014518630A5 (enExample) 2015-07-16
JP6254522B2 JP6254522B2 (ja) 2017-12-27

Family

ID=44310746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513202A Active JP6254522B2 (ja) 2011-06-01 2012-06-01 ヒト化抗cd52抗体

Country Status (16)

Country Link
US (1) US9321841B2 (enExample)
EP (1) EP2714739A1 (enExample)
JP (1) JP6254522B2 (enExample)
KR (1) KR20140036274A (enExample)
CN (1) CN103649122B (enExample)
AU (1) AU2012264643B2 (enExample)
BR (1) BR112013030875A2 (enExample)
CA (1) CA2837965A1 (enExample)
GB (1) GB201109238D0 (enExample)
IL (1) IL229713A (enExample)
MX (1) MX342676B (enExample)
MY (1) MY163257A (enExample)
RU (1) RU2605307C2 (enExample)
SG (1) SG195042A1 (enExample)
WO (1) WO2012164063A1 (enExample)
ZA (1) ZA201308900B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
CN106018814B (zh) * 2016-08-07 2017-11-14 深圳市南海生物科技有限公司 一种用于白血病和自身免疫病检测用试剂盒
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
EP3788074A1 (en) 2018-05-03 2021-03-10 Genmab B.V. Antibody variant combinations and uses thereof
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN117534750B (zh) * 2023-10-16 2024-06-11 遵义医科大学珠海校区 一种抗新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU9399501A (en) * 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗cd52抗体
EP1696956A4 (en) * 2003-12-22 2007-08-01 Genzyme Corp ANTI-CD52 ANTIBODIES AND TREATMENT OF DIABETES
JP2008528668A (ja) 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
US20090220520A1 (en) * 2005-05-24 2009-09-03 Villoo Morawala Patell Recombinant method for the production of a monoclonal antibody to CD52 for the treatment of chronic lymphocytic leukemia
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
CN102079787A (zh) * 2010-12-09 2011-06-01 协和干细胞基因工程有限公司 抗人cd52的工程抗体、载体、试剂盒及其用途

Similar Documents

Publication Publication Date Title
JP2014518630A5 (enExample)
RU2013158454A (ru) Гуманизированные антитела к сd52
JP2014512809A5 (enExample)
JP2020522261A5 (enExample)
US9771424B2 (en) ICOS binding proteins
TWI613217B (zh) Il-18結合分子
RU2013145243A (ru) Гуманизированные антитела к ctla4
CN112574307A (zh) 抗人Claudin18.2抗体及其应用
JP2021500916A5 (enExample)
CN103172738A (zh) Il-12/p40结合蛋白
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
CN109379892A (zh) 抗-IgE抗体
JP2015534982A5 (enExample)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
JP2016529882A5 (enExample)
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
TW201134489A (en) Basigin binding proteins
Teng et al. SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination
WO2021052465A1 (zh) 抗人cd38抗体及其应用
CN110494447A (zh) 使用抗人gpv1抗体抑制血小板聚集
US20210317405A1 (en) Methods for the production of therapeutic, diagnostic, or research antibodies
JP2020521752A (ja) グロボhに対するヒト化抗体および癌治療におけるその使用
Zhu Identification and Characterization of PF4/Heparin Reactive Antibodies in Heparin-Induce Thrombocytopenia Patients and COVID-19 Patients
RU2024107254A (ru) Модифицированное антитело против vegfr2 (kdr) и его применение